Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS other · 2025-12-17Clinical Trial Update: A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL [Phase 2]
Clinical trial update for a Phase 2 study of polatuzumab vedotin with rituximab and dose-attenuated CHP in older patients with diffuse large…
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating Rocbrutinib in participants with relapsed or refractory Non-GCB diffuse large B-cell lymphoma and is …
-
CLINICAL_TRIALS trial_result · 2025-12-11Clinical Trial Update: Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
This clinical trial update describes a nonconforming expanded access protocol for lisocabtagene maraleucel (CAR-T therapy) and notes that it…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) [Phase 3]
Phase 3 study evaluating safety and efficacy of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. The t…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL [Phase 2]
Phase 2 trial comparing Pola-RCHP-X to Pola-RCHP in previously untreated diffuse large B-cell lymphoma to assess efficacy and safety.
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating golcadomide, poseltinib, and rituximab for relapsed/refractory diffuse large B-cell lymphoma, wi…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta [Phase 1]
This Phase 1 trial seeks to optimize lymphodepletion strategies to improve outcomes for patients with diffuse large B-cell lymphoma receivin…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: PD-L1 PET-imaging During CAR T-cell Therapy [Phase 2]
Phase 2 clinical trial update investigating PD-L1 PET imaging during CAR T-cell therapy in diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update describing a multicenter, single-arm Phase I/II exploratory study to assess the safety and efficacy of a fully human B…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML [Phase 1, Phase 2]
This clinical trial update describes pediatric patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and diffuse large B-cell…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma [EARLY_Phase 1]
A Phase 1 trial assessing safety and preliminary efficacy of anti-EBV autologous TCR-T cell therapy in relapsed/refractory EBV-positive lymp…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: The TASTY-steering Study [NA]
A clinical trial update indicates that the TASTY-steering Study is currently recruiting for patients with metastatic triple-negative breast …
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL [Phase 2]
Phase 2 trial evaluating the combination of pirtobrutinib, lisaftoclax, and rituximab in relapsed/refractory diffuse large B-cell lymphoma, …
-
CLINICAL_TRIALS trial_result · 2025-12-01Clinical Trial Update: A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma [Phase 1]
The document reports a Phase 1 study of glofitamab in combination with rituximab plus Ifosfamide, Carboplatin, and Etoposide Phosphate in re…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
An expanded access program update for axicabtagene ciloleucel (Yescarta) for patients with diffuse large B-cell lymphoma and follicular lymp…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma [Phase 2]
This Phase 2 trial is evaluating the efficacy of axicabtagene ciloleucel in patients with late-relapse diffuse large B-cell lymphoma and is …
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma [Phase 2, Phase 3]
Xinlikang Capsule is being studied in Phase 2 and Phase 3 trials for chemotherapy-induced fatigue and immune disorders in patients with diff…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study of pevonedistat in combination with ibrutinib for relapsed or refractory chronic lympho…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for a glofitamab-based treatment in people with diffuse large B-cell lymphoma and high-grade B-cell lymphoma, …
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
Phase 2 clinical trial evaluating whether CD34+ cell dose influences absolute lymphocyte count after high-dose therapy and autologous stem c…
-
EMA approval · 2025-11-25EMA Authorised: Zynlonta (loncastuximab tesirine) — Swedish Orphan Biovitrum AB
The European Medicines Agency authorized Zynlonta (loncastuximab tesirine) for diffuse large B-cell lymphoma and B-cell lymphoma, under a co…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating loncastuximab tesirine and rituximab followed by DA-EPOCH-R for high-risk diffuse large B-cell lymphoma. Recruitmen…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating Tafasitamab and Lenalidomide followed by Tafasitamab and ICE as salvage therapy for transplant-elig…